Format

Send to

Choose Destination
Sci Rep. 2016 Dec 7;6:38133. doi: 10.1038/srep38133.

Activation induced deaminase mutational signature overlaps with CpG methylation sites in follicular lymphoma and other cancers.

Author information

1
National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.
2
Novosibirsk State University, Novosibirsk, Russia.
3
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA.
4
Department Microbiology and Molecular Genetics, University of California, Davis, CA, USA.
5
Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.
6
Department of Neurology and Systems Biology Center, Icahn School of Medicine at Mount Sinai, New York, USA.
7
Departments of Microbiology and Pathology, Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.

Abstract

Follicular lymphoma (FL) is an uncurable cancer characterized by progressive severity of relapses. We analyzed sequence context specificity of mutations in the B cells from a large cohort of FL patients. We revealed substantial excess of mutations within a novel hybrid nucleotide motif: the signature of somatic hypermutation (SHM) enzyme, Activation Induced Deaminase (AID), which overlaps the CpG methylation site. This finding implies that in FL the SHM machinery acts at genomic sites containing methylated cytosine. We identified the prevalence of this hybrid mutational signature in many other types of human cancer, suggesting that AID-mediated, CpG-methylation dependent mutagenesis is a common feature of tumorigenesis.

PMID:
27924834
PMCID:
PMC5141443
DOI:
10.1038/srep38133
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center